Insulin maker Novo Nordisk said its Ozempic diabetes drug had been included on a list of medicines approved for patients covered by U.S. private health schemes, setting the stage for a battle with Eli Lilly's Trulicity. Novo Nordisk, the world's biggest insulin maker, launched Ozempic, known generically as semaglutide, in the United States this year after it was approved by the U.S. Food and Drug Administration in December. Ozempic is a once-weekly injection that Novo Nordisk hopes will take market share from Trulicity, which has been cutting into sales of Novo Nordisk's once-daily Victoza.

M&A poses downside risks to the credit quality of Europe's six largest pharmaceutical companies in 2018 and will likely dampen any benefits from expected improvements in operating performance in the coming ...

On January 29, 2018, Sanofi (SNY) announced that it had agreed to acquire Ablynx (ABLX) for 3.9 billion euros. Ablynx and Sanofi had a successful existing partnership for multiple sclerosis research and immunoinflammatory diseases. Under the agreement terms, Sanofi gained access Ablynx’s scientists, certain nanobodies in its product portfolio, and Ablynx’s proprietary nanobody platform.

On January 29, 2018, Sanofi (SNY) announced its acquisition of Ablynx (ABLX), a Belgium-based biopharmaceutical company, for 45 euros per Ablynx share, amounting to a total of 3.9 billion euros (or $4.8 billion) in cash. As per the agreement, Sanofi will acquire all outstanding Ablynx ordinary shares, including American depositary shares, warrants, and convertible bonds. The deal was unanimously approved by the boards of directors of both Sanofi and Ablynx.

Sanofi (SNY) announced its acquisitions of Bioverativ and Ablynx in the last week of January 2018. The Bioverativ acquisition is valued at more than $11.6 billion, while the Ablynx acquisition is worth 3.9 billion euros. In this article, we’ll have a look at Wall Street’s recommendations and target prices following Sanofi’s Bioverativ acquisition announcement.

According to Sanofi’s (SNY) 2020 road map, the company is focused on sustaining a position of leadership in some of its key markets, including the rare diseases space. The company’s acquisition of Bioverativ (BIVV), which is aimed at expanding Sanofi’s leadership from genetic diseases into hemophilia, emphasizes this underlying goal.

After nearly a century building a company worth $125 billion based on injectable drugs, Denmark's Novo Nordisk - the world's biggest insulin maker - wants to prove this year it can transform the diabetes market with a pill. Novo's oral semaglutide medicine is important for ensuring the group's long-term growth - a critical mission after 2017 results last week revealed mounting price pressure in a crowded market targeting the world's 450 million diabetics. Rivals, especially Eli Lilly, are watching Novo's final-stage oral semaglutide trials closely, ahead of the drug's potential 2020 launch.

The company "had the need to expand our current capability at the facility," says Chad Henry, corporate vice president and general manager of Novo Nordisk in Clayton. "As our patient base continues to grow … we hope that we can expand in the future," Henry says. Chris Johnson, director of Johnston County Economic Development, says he believes Johnston County was selected again by Novo Nordisk for the new expansion because of the county's commitment to workforce development and its existing relationship with the Denmark-headquartered company.

On January 29, 2018, Sanofi entered an agreement with Ablynx where Sanofi will acquire all of the outstanding ordinary shares of Ablynx including American depositary shares (or ADSs), warrants, and convertible bonds. Sanofi will acquire Ablynx by purchasing Albynx’s share at a price of 45 euros per share in cash, which is equivalent to an equity value of approximately 3.9 billion euros. Ablynx is a biopharmaceutical company that specializes in the development of Nanobodies.